contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


revenio-buying-opportunity-long-portfolio

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Analyst

Juha Kinnunen

Revenio is a global provider of comprehensive eye care diagnostic solutions. The group offers fast, user-friendly, and reliable tools for diagnosing glaucoma, diabetic retinopathy, and macular degeneration (AMD). Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as software solutions under the iCare brand.

In 2023, the Group’s net sales totaled EUR 96.6 million, with an operating profit of EUR 26.3 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

I watched the interview and it seemed quite reasonable otherwise, despite the external factors. Is some kind of acquisition likely this year? But I didn’t grasp why the price increases in the US didn’t coincide with the tariffs. Was the old price locked into a signed contract or something? I don’t share the same view of the interim report as the market reaction. If I didn’t already own enough, I would have bought more today after such a beating.

And at Optomed’s current share price, the price wouldn’t be dizzying either…

Thanks for the great interview. It’s been stated directly before that inorganic growth is being actively pursued. But now, the wording of the dividend proposal was such that an acquisition is likely all but signed. The AGM is held on April 16th, and if the acquisition is finalized before then, the board can decide to skip the dividend distribution. In the Q&A section of the webcast, when Jouni was asked about acquisitions, he said that valuations have started to reach reasonable levels. He also mentioned that Robin has been working hard on these over the past quarters/years. Could it also be that Robin got an acquisition over the finish line and now is a good time to change companies?

I’m really excited to see what kind of acquisition is coming. It would be good if the same salespeople could have a larger portfolio to sell. Also, I think they have a good track record with integrations. But the current business is definitely very difficult.

-That was a good interview, thanks to Juha​ it became quite clear there that the product portfolio should be expanded on the device side. Targets have, of course, been scouted for a long time already, as long as the valuation is right. -One wouldn’t necessarily need to travel very far to go shopping. After all, Optomed is available right here, with a camera that already has FDA clearance​

It’s very clear that an acquisition is coming, looking at Jouni’s answers to the questions

Revenio’s Q4 results were weighed down by currency headwinds, delayed price increases in the US due to customs, and one-off costs. However, cash flow from operations was historically strong thanks to efficient working capital management. Revenio CEO Jouni Toijala comments on the company’s performance in an interview with analyst Juha Kinnunen.

Revenio Group

The share price has continued on a negative trend, while the company's valuation level (2024e adj. EV/EBIT ~15x) has decreased significantly. Since the August profit warning, Revenio's share has been declining, but we expect the situation to change as net sales return to an upward trajectory next year.

<p>The share price has continued on a negative trend, while the company's valuation level (2024e adj. EV/EBIT ~15x) has decreased significantly. Since the August profit warning, Revenio's share has been declining, but we expect the situation to change as net sales return to an upward trajectory next year.</p> 

	2022	23e	24e
Revenue	97.0	95.9	107.6
growth-%	23.1 %	-1.2 %	12.3 %
EBIT (adj.)	30.9	26.2	32.1
EBIT-% (adj.)	31.8 %	27.4 %	29.9 %
EPS (adj.)	0.86	0.74	0.93
Dividend	0.36	0.37	0.44
Dividend %	0.9 %	2.0 %	2.5 %
P/E (adj.)	44.6	24.3	19.3
EV/EBITDA	30.6	16.4	12.7

Revenio: Buying opportunity for a long portfolio

Key Estimate Figures2023-10-04

Forum discussions